Merck Still Vows To Fight Vioxx Cases One Suit At A Time
Merck is concerned about the potential strategies involved in multiple case trials, said the pharmaceutical company’s chief executive, Richard T. Clark, according to Dow Jones. He added that consolidated trials with different states, risk factors, preexisting conditions and other issues are extremely complex for a jury.
“We continue to work on convincing the judge that may not be an appropriate way to go,”...
To view the full article, register now.